In conclusion, we have demonstrated that the GEF activity of Vav1 is important for allogeneic T cell activation and proliferation. Disruption of Vav1 GEF activity in mice led to impaired alloreactivity and resulted in prolonged cardiac allograft survival. Our results show a significant contribution of Vav1 GEF activity to its role in T cell mediated rejection and indicate a potential novel way to induce immunosuppression by targeting Vav1 GEF activity. DH performed research and wrote
the paper; JP, TC, BM, ES, DK designed and performed research; VT and AS contributed mice and scientific input; GW initiated the concept and provided input to research and paper. The authors DH, PD0325901 JP, TC, BM, ES, DK and GW are employees of Novartis Pharma AG, Basel, Switzerland. All funding has been provided by Novartis Pharma AG, Basel, Switzerland. We thank Marinette Erard, Nadine Stohler and Patrick Gfeller for technical support. “
“The presence of anti-HLA antibodies in sera of solid organ transplant
recipients remains a well-documented risk factor for transplantation [1]. Because of this, the development of methods to detect the presence of anti-HLA antibodies has been a guiding motif for research since the beginning of clinical transplantation. As a result of this effort, several methods have been developed including complement-dependent cytotoxicity assay (CDC) [2], flow cytometry crossmatching [3], as well as many solid phase assays (SPAs) [4]. One of the solid phase assays uses multicolor
beads, each coated with a single class I or II HLA protein, to test previously sensitized patients’ sera to identify: (I) allelic HLA specificities of preformed Cobimetinib order Resveratrol antibodies; and (II) the relative reactivity patterns of these antibodies to define their clinical importance [4]. While the high sensitivity of such methods to detect very small quantities of anti-HLA antibodies seems very attractive, the clinical interpretation of their impact on allograft survival remains open. This is an especially pressing issue with the rise in numbers of highly sensitized patients on waiting lists [5]. The actual challenge is to find for each sensitized patient a matching donor with acceptable HLA alleles (against which patient has no preformed antibodies). To accomplish this goal, we need to identify a list of unacceptable (with strong reactivity) and acceptable (with weak or no reactivity) HLA alleles for each sensitized patient. Overall, the objective is to increase the number of transplants for highly sensitized patients without compromising the graft survival [6]. Another solution in the search for acceptable donors is the adoption of a concept of acceptable mismatches (AMMs), which have been extensively discussed elsewhere [7]. Indeed, the concept of AMMs follows the assumption that the recognition of epitopes on HLA molecules by antibodies occurs in discreet areas of the HLA molecules and some of these epitopes are identical on different HLAs [8].